GlassScriptPhysician profile
Satya D Patel
NPI 1952571341
$1,747.74
in general payments reported to CMS, 2019-2025
20 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.42 · 2023: $409 · 2024: $324 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,617 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,617.32 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $516.77 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $309.36 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $124.56 | 2024 | |
| Glaxosmithkline, LLC. | $122.13 | 2024-2025 | Trelegy Ellipta, Shingrix |
| Aimmune Therapeutics, INC. | $107.71 | 2025 | Zenpep |
| Amgen INC. | $96.64 | 2023-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $88.00 | 2019-2024 | |
| Corcept Therapeutics | $72.74 | 2025 | Korlym |
| Cequr Corporation | $46.22 | 2025 | Cequr Simplicity |
| Abbott Laboratories | $40.39 | 2023-2025 | Freestyle Libre 2, Octrode |
| Exact Sciences Corporation | $37.02 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $29.34 | 2025 | Jardiance, Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $25.54 | 2025 | |
| Eisai INC. | $24.71 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $23.61 | 2025 | Rexulti |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $18.57 | 2025 | |
| Dexcom, INC. | $17.74 | 2025 | Dexcom G6 Transmitter |
| Tolmar, INC. | $17.30 | 2025 | Jatenzo |
| Amneal Pharmaceuticals LLC | $15.27 | 2025 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.12 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satya Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.